Optimization of processing parameters for the development of Ficus religiosa L. extract loaded solid lipid nanoparticles using central composite design and evaluation of antidiabetic efficacy

Kumari, Priyanka; Sahu, Puran Lal; Singh, Sanjay

doi:10.1016/j.jddst.2017.08.006

Cited by 39 publications

(22 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Using cells of 10 mm diameter set at an angle of 90 • C at 25 • C, the mean diameter of the created SLNs was determined. By dispersing the particles through electrostatic repulsion, the zeta potential evaluates the electrophoretic mobility of any colloidal system (Priyanka et al, 2018). All measurements were carried out by first diluting them with distilled water and removing the air bubbles by sonication.…”

Section: Characterization Of Optimized Formulationmentioning

confidence: 99%

RETRACTED: QbD-based rivastigmine tartrate-loaded solid lipid nanoparticles for enhanced intranasal delivery to the brain for Alzheimer's therapeutics

Arora

Bhatt²,

Kumar³

et al. 2022

Front. Aging Neurosci.

View full text Add to dashboard Cite

Alzheimer's disease (AD) is a neurodegenerative disease that affects a wide range of populations and is the primary cause of death in various countries. The treatment of AD is still restricted to oral conventional medicines that act only superficially. Fabrication of intranasal solid lipid nanoparticulate system for the uptake of therapeutic agents will act as a convincing approach with limited off-site toxicity and increased pharmacological activity. The objective of this study was to formulate, optimize, and evaluate the efficiency of rivastigmine tartrate (RT)-loaded intranasal solid lipid nanoparticles (SLNs) employing the solvent-evaporation diffusion method. To optimize the formulation parameters, the central composite design (CCD) was used. Lipid concentration (X1) and surfactant concentration (X2) were considered to be independent variables, while particle size (Y1), percentage entrapment efficiency (Y2), and percentage drug release (Y3) were considered as responses. The solid lipid was glyceryl monostearate, while the surfactant was polysorbate 80. The optimized formulation has a particle size of 110.2 nm, % entrapment efficiency of 82.56%, and % drug release of 94.86%. The incompatibility of drug excipients was established by differential scanning calorimetry (DSC) and Fourier-transform infrared spectroscopy (FTIR). Nasal histopathology tests on sheep mucosa revealed that the developed SLNs were safe to utilize for intranasal delivery with no toxicity. Ex vivo permeation investigations revealed that the flux and diffusion coefficients for RT solid lipid nanoparticles and RT solution were 3.378 g/cm2 /h and 0.310–3 cm2 /h, respectively. Stability studies demonstrated that the developed SLNs were stable when stored under various storage conditions. The viability and vitality of adopting a lipid particle delivery system for improved bioavailability via the intranasal route were also established in the in vivo pharmacokinetic investigations. According to the histopathological and pharmacokinetic investigations, the developed formulations were safe, non-lethal, efficient, and robust. These results suggest the potentiality provided by rivastigmine tartrate-loaded solid lipid nanoparticles for nasal delivery.

show abstract

Section: Characterization Of Optimized Formulationmentioning

confidence: 99%

RETRACTED: QbD-based rivastigmine tartrate-loaded solid lipid nanoparticles for enhanced intranasal delivery to the brain for Alzheimer's therapeutics

Arora

Bhatt²,

Kumar³

et al. 2022

Front. Aging Neurosci.

View full text Add to dashboard Cite

show abstract

“…PDI is a measure of distribution of particle size. According to the literature, PDI greater than 0.5 indicates a polydisperse system, and if PDI is closer to zero, it indicates a monodisperse system [30][31][32]. In light of the literature, our results indicate that 0.466 is a favorable particle size (PDI <0.5).…”

Section: Particle Size and Zeta Potential Analysis Of Hpae-pcl-b-mpegsupporting

confidence: 55%

Design of an amphiphilic hyperbranched core/shell-type polymeric nanocarrier platform for drug delivery

et al. 2020

View full text Add to dashboard Cite

An amphiphilic core/shell-type polymer-based drug carrier system (HPAE-PCLb-MPEG), composed of hyperbranched poly(aminoester)-based polymer (HPAE) as the core building block and poly(ethylene glycol)bpoly(ε-caprolactone) diblock polymers (MPEGb-PCL) as the shell building block, was designed. The synthesized polymers were characterized with FTIR, 1 H NMR, 13 C NMR, and GPC analysis. Monodisperse HPAE-PCLb-MPEG nanoparticles with dimensions of <200 nm and polydispersity index of <0.5 were prepared by nanoprecipitation method and characterized with SEM, particle size, and zeta potential analysis. 5-Fluorouracil was encapsulated within HPAE-PCLb-MPEG nanoparticles. In vitro drug release profiles and cytotoxicity of blank and 5-fluorouracil-loaded nanoparticles were examined against the human colon cancer HCT116 cell line. All results suggest that HPAE-PCLb-MPEG nanoparticles offer an alternative and effective drug nanocarrier system for drug delivery applications.

show abstract

“…Results showed that extract loaded SLNs had pronounced hypoglycemic and insulin sensitizing effects compared with the extract suspension. The nanoformulations based on SLNs provided an initial burst release followed by sustained release (Priyanka et al, 2018). SLNs offer attractive properties including easy production, low particle size, low toxicity, and good loading capacity of active molecules (Gordillo-Galeano and Mora-Huertas, 2018).…”

Section: Diabetes Mellitusmentioning

confidence: 99%

Nanophytomedicines for the Prevention of Metabolic Syndrome: A Pharmacological and Biopharmaceutical Review

Nouri

Hajialyani

Izadi

et al. 2020

Front. Bioeng. Biotechnol.

View full text Add to dashboard Cite

Metabolic syndrome includes a series of metabolic abnormalities that leads to diabetes mellitus and cardiovascular diseases. Plant extracts, due to their unique advantages like anti-inflammatory, antioxidant, and insulin sensitizing properties, are interesting therapeutic options to manage MetS; however, the poor solubility and low bioavailability of lipophilic bioactive components in the herbal extracts are two critical challenges. Nano-scale delivery systems are suitable to improve delivery of herbal extracts. This review, for the first time, focuses on nanoformulations of herbal extracts in MetS and related complications. Included studies showed that several forms of nano drug delivery systems such as nanoemulsions, solid lipid nanoparticles, nanobiocomposites, and green-synthesized silver, gold, and zinc oxide nanoparticles have been developed using herbal extracts. It was shown that the method of preparation and related parameters such as temperature and type of polymer are important factors affecting physicochemical stability and therapeutic activity of the final product. Many of these formulations could successfully decrease the lipid profile, inflammation, oxidative damage, and insulin resistance in in vitro and in vivo models of MetS-related complications. Further studies are still needed to confirm the safety and efficacy of these novel herbal formulations for clinical application.

show abstract

Optimization of processing parameters for the development of Ficus religiosa L. extract loaded solid lipid nanoparticles using central composite design and evaluation of antidiabetic efficacy

Cited by 39 publications

References 10 publications

RETRACTED: QbD-based rivastigmine tartrate-loaded solid lipid nanoparticles for enhanced intranasal delivery to the brain for Alzheimer's therapeutics

RETRACTED: QbD-based rivastigmine tartrate-loaded solid lipid nanoparticles for enhanced intranasal delivery to the brain for Alzheimer's therapeutics

Design of an amphiphilic hyperbranched core/shell-type polymeric nanocarrier platform for drug delivery

Nanophytomedicines for the Prevention of Metabolic Syndrome: A Pharmacological and Biopharmaceutical Review

Contact Info

Product

Resources

About